Research Analysts Offer Predictions for Charles River Laboratories Intl. Inc’s Q2 2019 Earnings (NYSE:CRL)

Share on StockTwits

Charles River Laboratories Intl. Inc (NYSE:CRL) – Research analysts at Svb Leerink issued their Q2 2019 earnings estimates for Charles River Laboratories Intl. in a research note issued to investors on Monday, June 10th. Svb Leerink analyst D. Larsen forecasts that the medical research company will post earnings per share of $1.58 for the quarter. Svb Leerink has a “Outperform” rating and a $155.00 price objective on the stock. Svb Leerink also issued estimates for Charles River Laboratories Intl.’s Q3 2019 earnings at $1.69 EPS, Q4 2019 earnings at $1.83 EPS, FY2019 earnings at $6.50 EPS, Q1 2020 earnings at $1.58 EPS, Q2 2020 earnings at $1.87 EPS, Q3 2020 earnings at $1.92 EPS, Q4 2020 earnings at $2.02 EPS, FY2020 earnings at $7.40 EPS and FY2021 earnings at $8.30 EPS.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Tuesday, May 7th. The medical research company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.38 by $0.02. The business had revenue of $604.57 million during the quarter, compared to analyst estimates of $587.65 million. Charles River Laboratories Intl. had a return on equity of 23.03% and a net margin of 9.63%. The company’s revenue was up 22.4% compared to the same quarter last year. During the same period last year, the company posted $1.29 EPS.

Several other equities research analysts have also weighed in on CRL. Jefferies Financial Group reissued a “buy” rating and set a $162.00 price objective on shares of Charles River Laboratories Intl. in a research note on Thursday, February 14th. SunTrust Banks raised their price objective on Charles River Laboratories Intl. to $151.00 and gave the stock a “buy” rating in a research note on Thursday, February 14th. Barclays reaffirmed a “hold” rating and issued a $135.00 target price on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. Zacks Investment Research raised Charles River Laboratories Intl. from a “sell” rating to a “hold” rating and set a $156.00 target price for the company in a research report on Thursday, February 14th. Finally, KeyCorp raised their target price on Charles River Laboratories Intl. from $140.00 to $151.00 and gave the stock an “overweight” rating in a research report on Monday, March 11th. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and a consensus price target of $146.27.

CRL opened at $132.86 on Tuesday. The firm has a market cap of $6.25 billion, a PE ratio of 22.03, a P/E/G ratio of 1.65 and a beta of 1.05. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.63 and a quick ratio of 1.39. Charles River Laboratories Intl. has a fifty-two week low of $103.00 and a fifty-two week high of $149.07.

In other news, insider William D. Barbo sold 4,905 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total value of $613,909.80. Following the completion of the sale, the insider now owns 25,859 shares of the company’s stock, valued at $3,236,512.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director George Massaro sold 3,140 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $134.64, for a total value of $422,769.60. Following the completion of the sale, the director now directly owns 15,344 shares of the company’s stock, valued at approximately $2,065,916.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,047 shares of company stock valued at $1,168,322. 1.80% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the stock. Tompkins Financial Corp raised its holdings in shares of Charles River Laboratories Intl. by 63.1% during the first quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock worth $27,000 after acquiring an additional 77 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Charles River Laboratories Intl. by 0.8% during the first quarter. Louisiana State Employees Retirement System now owns 12,900 shares of the medical research company’s stock worth $1,874,000 after acquiring an additional 100 shares in the last quarter. State Treasurer State of Michigan raised its holdings in shares of Charles River Laboratories Intl. by 0.6% during the first quarter. State Treasurer State of Michigan now owns 17,200 shares of the medical research company’s stock worth $2,498,000 after acquiring an additional 100 shares in the last quarter. Kwmg LLC raised its holdings in shares of Charles River Laboratories Intl. by 32.4% during the fourth quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock worth $49,000 after acquiring an additional 105 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Charles River Laboratories Intl. by 0.3% during the first quarter. Arizona State Retirement System now owns 34,629 shares of the medical research company’s stock worth $5,030,000 after acquiring an additional 109 shares in the last quarter. Institutional investors and hedge funds own 94.72% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: What are different types of coverage ratios?

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.